BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Focus

New Post Public Reply Private Reply Replies (0) Message Board
NetworkNewsWire
235
BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Focus with Development of New NanoAb Therapeutics

- Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs
- BiondVax enjoys an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder the RCA
- The company recently announced intent to develop innovative NanoAbs targeting immune system cytokines such as IL-17 for the potential treatment of psoriasis and psoriatic arthritis
- Analysts at Zacks Small-Cap Research laud the shift in focus to anti-IL-17 and have pegged the stock to reach $8 per share from current levels of below $2 per share

Last September, a joint steering committee comprising professionals from BiondVax Pharmaceuticals (NASDAQ: BVXV), the Max Planck Institute for Multidisciplinary Sciences (“MPG”), and the University Medical Center Göttingen (“UMG”), made a decision. Established to guide the BVXV-MPG-UMG NanoAb collaboration, the committee decided to focus the nanosized antibody (“NanoAb”) development on other therapeutic indications in addition to COVID-19. This renewed focus would begin with the development of NanoAbs targeting immune system cytokines such as IL-17 (IL-17A, IL-17F, and IL-17A/F) for the potential treatment of psoriasis and psoriatic arthritis and IL-13 for the potential treatment of asthma (https://nnw.fm/ZKKxj ).

The committee’s decision is anchored in a five-year definitive research collaboration agreement (“RCA”) entered between BVXV, a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, and its collaborators, MPG and UMG, allowing the company to exercise an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder (https://nnw.fm/cqqB6 ).

BiondVax’s decision to focus on developing additional NanoAb therapies was featured in new updated coverage by Zacks Small-Cap Research (https://nnw.fm/jCncV ). The research report highlighted the company’s recent announcement regarding its intention to exercise the option to obtain an exclusive license to NanoAbs targeting IL-17 and other system cytokines. This announcement aligns with the company’s de-risked strategy, which includes pursuing biobetter drugs for against biological targets that are already proven to exert beneficial clinical results in humans when treated with conventional monoclonal antibodies (“mAbs”). Additionally, and in line with this strategy, the company intends to capitalize on NanoAbs’ status as potential “bio-betters” that offer potential advantages over mAbs, given their stability, extremely high binding affinity with effective neutralization, and high specificity.

The company has so far gathered significant data about the potential efficacy and capabilities of NanoAbs, thanks to its preclinical in vivo proof-of-concept study evaluating the effect of its inhaled anti-COVID-19 NanoAb therapy. The study, which utilized the industry-standard Syrian hamster model of SARS-CoV-2 infection, showed that the therapy virtually eliminated the virus from the lungs (https://nnw.fm/s2jOf ), caused milder and shorter illness (https://nnw.fm/M0yRt ), and had prophylactic properties (https://nnw.fm/gCsoz ). Based on these encouraging findings, BiondVax is evaluating plans to commence a Phase 1/2a clinical trial, albeit with a keen eye on the mutation of the virus and the emergence of new variants of concern (“VoCs”).

The Zacks report lauds the shift to focus on the anti-IL-17 NanoAb as a “good decision.” By announcing its intention to exercise the option for an additional NanoAb, BiondVax is expanding its pipeline potential while mitigating certain risks to its business and diversifying its portfolio of possible block buster therapies.

Meanwhile, BVXV released its financial results for the first quarter of 2023, reporting cash and cash equivalents of $10.9 million, which analysts at Zacks estimate are sufficient to fund the company’s operations through the first quarter of 2024. An astute business practitioner as well as biotech innovator, BiondVax aims to maximize assets and increase revenues by offering its state-of-the-art cGMP manufacturing services to interested parties which could easily engender new strategic alliances as well as bolster the bottom line.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://nnw.fm/BVXV

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


BiondVax Pharmaceuticals Ltd. (BVXV) Stock Research Links

BVXV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

LLCP Backs Empower in UK Infrastructure Services Push

Updated Category News Views 71

A majority cheque has landed in a business built around unglamorous work that cannot be wished away: keeping mechanical and electrical systems installed, refurbished and maintained. On November 18, LLCP said it completed a majority investment in London-headquartered Empower Technical Services alongside chief executive Nicholas Manning, co-founders Florian Kronawitter and...

Continue Reading
Workday GO for Financials Targets the Messy Middle

Updated Category News Views 160

Spreadsheets rarely die gracefully; they get buried under approvals, reconciliations, and the frantic scavenger hunt before an audit. Workday is aiming straight at that unpleasant moment with Workday GO for Financials, announced November 18 at Workday Rising EMEA in Barcelona. The pitch is not terribly romantic, thank goodness. It is a simpler way for growing companies to...

Continue Reading
Epsium's Inventory Pile Looms Over Weak First Half

Updated Category News Views 18

A warehouse full of bottles is not a balance-sheet fortress when buyers are backing away. Epsium Enterprise’s first-half 2026 report is a rough read: revenue collapsed 51.8% to $1.47 million, gross profit fell to $175,353, and cash slid to $612,761 at June 30. This is not a subtle slowdown. Macau’s premium Chinese-liquor market has been weak on both demand and...

Continue Reading
Clarivate's 2026 Research List Carries a Trust Test

Updated Category News Views 209

Seven thousand ninety awards can look like a victory lap until you remember how easily raw citation counts can be gamed. Clarivate’s 2026 Highly Cited Researchers list is more interesting for its insistence on screening than for the familiar names at the top. In a research world where publication volume, self-citation and paper mills have made plenty of people...

Continue Reading
Clorox Boosts Payout With Steady $1.25 Dividend

Updated Category News Views 221

Quarterly Dividends: A Clorox Tradition It seems you can't talk about Clorox (NYSE: CLX) without mentioning its steadfast dedication to shareholders. Once again, this 113-year-old stalwart is back on the map with its juicy quarterly dividend—$1.25 per share, to be precise. That's scheduled to hit your account by February 12, 2027, if you're on the books by the end of...

Continue Reading
Novo and nference Push Whole-Body Data Into Research

Updated Category News Views 26

Cardiometabolic medicine has spent too long staring at single numbers while the rest of the body keeps waving its arms. Novo Nordisk’s newly announced collaboration with nference is an attempt to widen that lens, combining Novo’s clinical-trial research with nference’s AI technology and federated healthcare data network. The target is not small: obesity, diabetes,...

Continue Reading
Disney Springs Hotel Rates Test Holiday Demand Depth

Updated Category News Views 112

A $145 room rate is the sort of holiday bait that gets my attention before the fake snow does. Disney Springs Resort Area Hotels are extending a seasonal offer for stays through Dec. 18, 2026, with bookings open only through Nov. 20. That is a very narrow selling window, and it tells you plenty: these seven independent hotels want to fill rooms during a lucrative but...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 93

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 173

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Stardock Fences 7 Targets Messy Windows Desktops Everywhere

Updated Category News Views 77

A cluttered Windows desktop is a tiny tax on attention, and Stardock has spent three decades selling people a way around it. Fences 7, released November 18, 2026, is the latest swing: a Windows 11-focused update that combines cosmetic polish with a genuinely practical privacy feature. This is not grand enterprise software, and nobody should pretend a $10 desktop utility...

Continue Reading

Top 5 Most Recently Viewed Articles

CareConnect Unveils Revolutionary Home Care Insights Platform

Updated Category News Views 233

CareConnect unveils Home Care Insights CareConnect, LLC—known for AI-driven home care software and services—has introduced Home Care Insights, a new way to see and manage the caregiver workforce. The goal is simple: give agencies timely, usable insight into recruitment, engagement, and retention so they can staff confidently and deliver dependable care. Home Care...

Continue Reading
Dragon Boats and Poetry: Yichang's Festival Unleashed

Updated Category News Views 58

Yichang's Grand Festival: A Cultural Tapestry Unfolds In a world that's constantly spinning with change, there's something comforting about tradition. On June 21, Yichang in central China's Hubei Province, lit up with a flurry of festivities as the Dragon Boat Festival kicked off. Now, this isn't just about boats skimming down a river. It's a celebration that knits...

Continue Reading
Corero Network Security Expands Growth with $6 Million Orders

Updated Category News Views 187

Corero Network Security Announces New Orders Corero Network Security, a renowned provider in the field of DDoS protection, recently marked a significant milestone by securing $6 million in new orders, demonstrating its ongoing growth and success. This achievement comes as the company wraps up the third quarter of 2024, bringing its total orders for the year to an...

Continue Reading
Iridex's Innovative Study on MicroPulse Treatment for DME

Updated Category News Views 181

Revolutionizing Diabetic Macular Edema Treatment MOUNTAIN VIEW, Calif. – Iridex Corporation (Nasdaq: IRIX), a leader in laser-based medical systems, has taken a remarkable step forward in the treatment of diabetic macular edema (DME). The company recently announced the successful enrollment of the first patient in the DAME Trial. This pivotal study aims to assess the...

Continue Reading
Envision Energy Partners with TÜV Nord to Enhance Wind Power Innovation

Updated Category News Views 120

Envision Energy Partners with TÜV Nord for Wind Power Innovation In a move sending ripples through the renewable energy sector, Envision Energy recently teamed up with TÜV Nord at the WindEnergy Hamburg event. Their signing of a cooperation memorandum marks not just paperwork, but a serious commitment to reshape the landscape of wind power technology. What's Fueling...

Continue Reading